fc1

BFC1108 targets Bcl-2 and converts it to a pro-apoptotic protein, inhibits the growth of triple-negative breast cancer xenografts with high Bcl-2 expression, inhibits breast cancer lung metastasis, and induces apoptosis of Bcl-2-expressing cancer cells.

CXCR4 antagonist

FC11409B is a CAIX inhibitor, inhibiting breast cancer invasion and metastasis.

FC131 TFA is a CXCR4 antagonist, inhibits [ 125 I]-SDF-1 binding to CXCR4 , with an IC 50 of 4.5 nM. Anti- HIV activity [1] .

FC14-584B, a dithiocarbamate and β-Carbonic Anhydrase inhibitor, impedes the growth of trophozoites and can be utilized for tuberculosis research [1].

BFC1103 is a small molecule compound that primarily interacts with a specific domain of Bcl-2, particularly its loop domain. This interaction causes a conformational change in Bcl-2, exposing its BH3 (Bcl-2 homologous 3) domain and switching Bcl-2's function from anti-apoptotic to pro-apoptotic. The cell death induced by BFC1103 is dependent on the presence of either Bax or Bak, both of which are crucial proteins in the mitochondrial-mediated intrinsic apoptosis pathway. In mouse models, BFC1103 effectively inhibited lung metastasis of triple-negative breast cancer. BFC1103 can be used to study the role of Bcl-2 family proteins in cancer development and their impact on cancer cell survival and proliferation.

FC131 TFA (606968-52-9 free base) (FC131 TFA) is an antagonist of CXCR4 that inhibits the binding of [125I] -sdf-1 to CXCR4(IC50 : 4.5 nM ), and has anti-hiv activity.

3-CPMT (FC-1) is a dopamine uptake inhibitor and a potent long-acting antihistaminic agent.